US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancerGlobeNewsWire • 10/15/21
FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung CancerBusiness Wire • 10/15/21
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient careGlobeNewsWire • 10/15/21
New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorderGlobeNewsWire • 10/14/21
Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphomaGlobeNewsWire • 10/14/21
New 4-Year Data Show Genentech's Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum DisorderBusiness Wire • 10/14/21
Data up to 8-years for Roche's OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosisGlobeNewsWire • 10/13/21
New Data up to 8-Years for Genentech's Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple SclerosisBusiness Wire • 10/13/21
Genentech's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer's DiseaseBusiness Wire • 10/08/21
[Ad hoc announcement pursuant to Art. 53 LR] Roche's anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's diseaseGlobeNewsWire • 10/08/21
Ad hoc announcement pursuant to Art. 53 LR: Genentech's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer's DiseaseBusiness Wire • 10/08/21
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021GlobeNewsWire • 10/05/21
Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021Business Wire • 10/05/21
Roche says Phase 2/3 trial of COVID treatment Ronapreve met its primary endpointMarket Watch • 09/30/21
Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19GlobeNewsWire • 09/30/21
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy PatientsBenzinga • 09/24/21
Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disordersGlobeNewsWire • 09/24/21
Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patientsGlobeNewsWire • 09/22/21
New Phase III data support the benefit of Roche's Tecentriq in early-stage lung cancerGlobeNewsWire • 09/20/21
New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-stage Lung CancerBusiness Wire • 09/20/21
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancerGlobeNewsWire • 09/17/21